findmyKOL
Clinical trialNCT02678572CompletedPhase 3Interventional

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

SponsorDelcath Systems Inc.Enrollment102Melanoma, Ocular
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Austria
  • Universitätsklinikum Graz

    Graz, Austria

Belgium
  • Universitair Ziekenhuis Leuven

    Leuven, Belgium

France
  • Centre Léon Bérard

    Lyon, Rhône, France

Germany
  • Charité Unversitätsmedizin Berlin Comprehensive Cancer Center

    Berlin, Germany

  • Universitätsklinikum Giessen Und Marburg

    Marburg, Germany

  • Universitätshautklinik Münster

    Münster, Germany

  • Universitätsklinikum Regensburg

    Regensburg, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

Italy
  • Istituto Europeo Di Oncologia

    Milan, Italy

Spain
  • Clínic Barcelona

    Barcelona, Spain

  • Hospital Ramón Y Cajal

    Madrid, Spain

Switzerland
  • Universitätsspital Zürich

    Zurich, Switzerland

United Kingdom
  • University Hospital Southampton Nhs Trust

    Southampton, Hampshire, United Kingdom

  • Aintree University Hospital

    Liverpool, United Kingdom

United States
  • University of Arizona

    Tucson, Arizona, United States

  • Stanford University

    Palo Alto, California, United States

  • Moffitt Cancer Center

    Tampa, Florida, United States

  • Emory University

    Atlanta, Georgia, United States

  • University of Chicago

    Chicago, Illinois, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • Ohio State University James Cancer Center

    Columbus, Ohio, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, United States

  • University of Tennessee Health Science Center

    Memphis, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Feb 2016
Primary completion
18 May 2023
Completion
15 Aug 2023
Last update posted
21 Dec 2023
Registered enrollment
102
Registry id
NCT02678572
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.